368 related articles for article (PubMed ID: 25155935)
1. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
[TBL] [Abstract][Full Text] [Related]
2. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
4. Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Mol Biol Rep; 2014 Nov; 41(11):7305-12. PubMed ID: 25069408
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
6. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics; 2015 Jul; 25(7):343-353. PubMed ID: 25946405
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
9. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
[TBL] [Abstract][Full Text] [Related]
10. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
Ivashchenko D; Rusin I; Sychev D; Grachev A
Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
[TBL] [Abstract][Full Text] [Related]
11. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
12. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
13. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
[TBL] [Abstract][Full Text] [Related]
15. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
17. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
20. Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S; Diaz-Ordoñez L; Silva-Cuero YK; Gutierrez-Medina JD; Candelo E; Diaz JA; Pachajoa H
Medicine (Baltimore); 2023 Jul; 102(30):e34204. PubMed ID: 37505171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
